Analysis of apolipoprotein A5, C3, and plasma triglyceride concentrations in genetically engineered mice

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 24, Issue 7, 2004, Pages 1297-1302

  Baroukh, Nadine ^a   Bauge, Eric ^b   Akiyama, Jennifer ^a   Chang, Jessie ^a   Afzal, Veena ^a   Fruchart, Jean Charles ^b   Rubin, Edward M ^a,c   Fruchart Najib, Jamila ^b   Pennacchio, Len A ^a,c  

^a LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^b INSTITUT PASTEUR DE LILLE   (France)

^c DOE JOINT GENOME INSTITUTE   (United States)

Author keywords

Apolipoprotein; Transgenic mice; Triglyceride

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN A5; APOLIPOPROTEIN C3; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; GENE DELETION; GENE OVEREXPRESSION; GENETIC ENGINEERING; KNOCKOUT MOUSE; LIPID METABOLISM; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; APOLIPOPROTEIN C-III; APOLIPOPROTEINS; APOLIPOPROTEINS A; APOLIPOPROTEINS C; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; RECOMBINANT FUSION PROTEINS; TRIGLYCERIDES;

EID: 3042817124     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000130463.68272.1d     Document Type: Article

References (29)

1. Luo CC, Li WH, Moore MN, Chan L. Structure and evolution of the apolipoprotein multigene family. J Mol Biol. 1986;187:325-340.
2. Pennacchio LA, Olivier M, Hubacek JA, Cohen JC, Cox DR, Fruchart JC, Krauss RM, Rubin EM. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science. 2001; 294:169-173.
3. Bruns GA, Karathanasis SK, Breslow JL. Human apolipoprotein A-I-C-III gene complex is located on chromosome II. Arteriosclerosis. 1984;4:97-102.
4. Weinstock PH, Bisgaier CL, Hayek T, Aalto-Setala K, Sehayek E, Wu L, Sheiffele P, Merkel M, Essenburg AD, Breslow JL. Decreased HDL cholesterol levels but normal lipid absorption, growth, and feeding behavior in apolipoprotein A-IV knockout mice. J Lipid Res. 1997;38: 1782-1794.
5. Duverger N, Tremp G, Caillaud JM, Emmanuel F, Castro G, Fruchart JC, Steinmetz A, Denefle P. Protection against atherogenesis in mice mediated by human apolipoprotein A-IV. Science. 1996;273:966-968.
6. Endo K, Yanagi H, Araki J, Hirano C, Yamakawa-Kobayashi K, Tomura S. Association found between the promoter region polymorphism in the apolipoprotein A-V gene and the serum triglyceride level in Japanese schoolchildren. Hum Genet. 2002;111:570-572.
7. Nabika T, Nasreen S, Kobayashi S, Masuda J. The genetic effect of the apoprotein AV gene on the serum triglyceride level in Japanese. Atherosclerosis. 2002;165:201-204.
8. Pennacchio LA, Olivier M, Hubacek JA, Krauss RM, Rubin EM, Cohen JC. Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels. Hum Mol Genet. 2002;11:3031-3038.
9. Pennacchio LA, Rubin EM. Apolipoprotein A5: A newly identified gene impacting plasma triglyceride levels in humans and mice. Arterioscler Thromb Vasc Biol. 2003;23:529-534.
10. Ribalta J, Figuera L, Fernandez-Ballart J, Vilella E, Castro Cabezas M, Masana L, Joven J. Newly identified apolipoprotein AV gene predisposes to high plasma triglycerides in familial combined hyperlipidemia. Clin Chem. 2002;48:1597-1600.
11. Talmud PJ, Hawe E, Martin S, Olivier M, Miller GJ, Rubin EM, Pennacchio LA, Humphries SE. Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides. Hum Mol Genet. 2002;11:3039-3046.
12. Maeda N, Li H, Lee D, Oliver P, Quarfordt SH, Osada J. Targeted disruption of the apolipoprotein C-III gene in mice results in hypertriglyceridemia and protection from postprandial hypertriglyceridemia. J Biol Chem. 1994;269:23610-23616.
13. Ito Y, Azrolan N, O'Connell A, Walsh A, Breslow JL. Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. Science. 1990;249:790-793.
14. Vergnes L, Baroukh N, Ostos MA, Castro G, Duverger N, Nanjee MN, Najib J, Fruchart JC, Miller NE, Zakin MM, Ochoa A. Expression of human apolipoprotein A-I/C-III/A-IV gene cluster in mice induces hyperlipidemia but reduces atherogenesis. Arterioscler Thromb Vasc Biol. 2000;20:2267-2274.
15. Xu CF, Talmud P, Schuster H, Houlston R, Miller G, Humphries S. Association between genetic variation at the APO AI-CIII-AIV gene cluster and familial combined hyperlipidaemia. Clin Genet. 1994;46: 385-397.
16. Wojciechowski AP, Farrall M, Cullen P, Wilson TM, Bayliss JD, Farren B, Griffin BA, Caslake MJ, Packard CJ, Shepherd J, Thakker R, Scott J. Familial combined hyperlipidaemia linked to the apolipoprotein AI-CII-AIV gene cluster on chromosome 11q23-q24. Nature. 1991;349: 161-164.
17. Hayden MR, Kirk H, Clark C, Frohlich J, Rabkin S, McLeod R, Hewitt J. DNA polymorphisms in and around the Apo-AI-CIII genes and genetic hyperlipidemias. Am J Hum Genet. 1987;40:421-430.
18. Ferns GA, Stocks J, Galton DJ. C-III DNA restriction fragment length polymorphism and myocardial infarction. Lancet. 1986;1:94.
19. Dammerman M, Sandkuijl LA, Halaas JL, Chung W, Breslow JL. An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3′ untranslated region polymorphisms. Proc Natl Acad Sci USA. 1993;90:4562-4566.
20. Allayee H, Aouizerat BE, Cantor RM, Dallinga-Thie GM, Krauss RM, Lanning CD, Rotter JI, Lusis AJ, de Bruin TW. Families with familial combined hyperlipidemia and families enriched for coronary artery disease share genetic determinants for the atherogenic lipoprotein phenotype. Am J Hum Genet. 1998;63:577-585.
21. Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature. 1991;353:265-267.
22. Ebara T, Ramakrishnan R, Steiner G, Shachter NS. Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E. J Clin Invest. 1997;99:2672-2681.
23. Ikeda T, Shibuya Y, Senba U, Sugiuchi H, Araki S, Uji Y, Okabe H. Automated immunoturbidimetric analysis of six plasma apolipoproteins: correlation with radial immunodiffusion assays. J Clin Lab Anal. 1991; 5:90-95.
24. Marz W, Schenk G, Gross W. Apolipoproteins C-II and C-III in serum quantified by zone immunoelectrophoresis. Clin Chem. 1987;33: 664-669.
25. Sakurabayashi I, Saito Y, Kita T, Matsuzawa Y, Goto Y. Reference intervals for serum apolipoproteins A-I, A-II, B, C-II, C-III, and E in healthy Japanese determined with a commercial immunoturbidimetric assay and effects of sex, age, smoking, drinking, and Lp(a) level. Clin Chim Acta. 2001;312:87-95.
26. Baum L, Tomlinson B, Thomas G. APOA5-1131T>C polymorphism is associated with triglyceride levels in Chinese men. Clin Genet. 2003;63: 377-379.
27. Aouizerat BE, Kulkarni M, Heilbron D, Drown D, Raskin S, Pullinger CR, Malloy MJ, Kane JP. Genetic analysis of a polymorphism in the human apolipoprotein A-V gene: effect on plasma lipids. J Lipid Res. 2003.
28. Masana L, Ribalta J, Salazar J, Fernandez-Ballart J, Joven J, Cabezas MC. The apolipoprotein AV gene and diumal triglyceridaemia in normolipidaemic subjects. Clin Chem Lab Med. 2003;41:517-521.
29. Allain CC, Poon LS, Chan CS, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem. 1974;20:470-475.